A forum for researchers, students and applicants in the field of cyclodextrin technology
Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary
The Lancet published on an open-label, parallel-group, phase 2, randomised controlled trial, on inhaled budesonide (Ramakrishnan et al. 2021). Participants
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Niemann–Pick disease type C (NPC) is a recessive hereditary disease caused by mutation of the NPC1 or NPC2 gene. It is characterized by abnormality
Drug Development and Delivery has published on excipients with the title: SPECIAL FEATURE – Excipients: Far From Inactive summarizing the
The Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
DMDS is a natural biological pesticide formed by the decomposition of soil fungi and bacteria. It controls soil nematodes and
Drug Development & delivery published on the virtual 2020 Global Drug Bioavailability Enhancement Summit, which this past December showcased novel
